Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

0.9303 UNCHANGED

Delayed Quote Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics ↗

January 31, 2025

Via Benzinga

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

January 27, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Issues Letter to Stockholders

January 06, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts ↗

January 03, 2025

Via Benzinga

Lineage Cell Therapeutics's Earnings Outlook ↗

November 13, 2024

Via Benzinga

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

November 21, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 20, 2024

Via Benzinga

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 14, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

November 20, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

November 07, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

October 14, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

September 18, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

September 25, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

August 13, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 08, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

August 01, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

July 02, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage to Present at 2024 BIO International Convention

May 30, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

May 21, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 09, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 06, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

May 02, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Changes to Board of Directors

April 29, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

April 30, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

April 01, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

March 18, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

March 13, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.